Select Apple 10-year bonds currently yield about 5.20%, while some Meta 10-years yield 5.75%
Investors are flocking to bonds issued by of the Magnificent Seven companies, drawn in by some of the juiciest yields seen on such high-quality names.
From the archive : Magnificent Seven tech stocks haven’t been this cheap in six years, Goldman Sachs strategists say Of that group, only Microsoft and Nvidia pay dividends, but the implied yield on Microsoft’s stock is 0.90% and on Nvidia’s stock is just 0.04%. For investors, it means the opportunity to add these high-yielding, high-quality names to portfolios at a discount.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Apple launches cheaper $79 Apple Pencil with hidden USB-C charging portApple is launching a new Apple Pencil with a USB-C charging port, the company announced Tuesday.
Weiterlesen »
Apple announces entry-level Apple Pencil with USB-C chargingThe new USB-C Apple Pencil supports hover and lacks pressure sensitivity but is a less annoying to charge Pencil that magnetically attaches to the side of the 10th-gen iPad.
Weiterlesen »
Apple unveils universal USB-C Apple Pencil that works with every iPadApple is finally releasing a universal Apple Pencil to all iPad models. Here's how it works compared to the other models.
Weiterlesen »
Apple launches cheaper $79 Apple Pencil with hidden USB-C charging portApple is launching a new Apple Pencil with a USB-C charging port, the company announced Tuesday.
Weiterlesen »
Apple to update iPhone units inside Apple Stores without opening the boxesAlan, an ardent smartphone enthusiast and a veteran writer at PhoneArena since 2009, has witnessed and chronicled the transformative years of mobile technology. Owning iconic phones from the original iPhone to the iPhone 11 Pro Max, he has seen smartphones evolve into a global phenomenon.
Weiterlesen »
UBS upgrades this 'core' health care stock, sees nearly 20% upsideThe firm upgraded shares of the health care giant to buy from neutral and raised its target price to $640 from $520.
Weiterlesen »